A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) | MicrobiomeTrials
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-11-20Est. Completion: 2026-08-11
Enrollment target: 83 participants
Locations
Local Institution - 0031, Anjo-shi, Aichi-ken, Japan
Local Institution - 0011, Nagoya, Aichi-ken, Japan
Local Institution - 0024, Toyohashi, Aichi-ken, Japan
Local Institution - 0017, Kamogawa, Chiba, Japan
Local Institution - 0002, Kashiwa, Chiba, Japan
Local Institution - 0037, Narita, Chiba, Japan
Local Institution - 0016, Iizuka, Fukuoka, Japan
Local Institution - 0041, Kitakyushu-shi, Fukuoka, Japan
Local Institution - 0036, Sapporo, Hokkaido, Japan
Local Institution - 0032, Amagasaki, Hyōgo, Japan
Local Institution - 0033, Kobe, Hyōgo, Japan
Local Institution - 0004, Isehara, Kanagawa, Japan
Local Institution - 0013, Yokosuka, Kanagawa, Japan
Local Institution - 0001, Sendai, Miyagi, Japan
Local Institution - 0019, Ōmura, Nagasaki, Japan
Local Institution - 0028, Sasebo, Nagasaki, Japan
Local Institution - 0005, Ōsaka-sayama, Osaka, Japan
Local Institution - 0009, Hidaka, Saitama, Japan
Other microbiome trials you might be interested in
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin …
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic InflammationDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedEBV-Positive Mucocutaneous UlcerHHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedIntravascular Large B-Cell LymphomaLarge B-Cell Lymphoma With 11q AberrationLarge B-Cell Lymphoma With IRF4 RearrangementPlasmablastic LymphomaPrimary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemPrimary Effusion LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Gray-Zone LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent Lymphomatoid GranulomatosisRecurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRecurrent Primary Mediastinal Large B-Cell LymphomaRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Gray-Zone LymphomaRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRefractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRefractory Primary Mediastinal Large B-Cell LymphomaRefractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-c…
Phoenix, United StatesEst. completion May 26, 2023